• Citer

Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis

par Saad, Everardo Delforge;Squifflet, Pierre;Burzykowski, Tomasz;Quinaux, Emmanuel;Delaloge, Suzette;Mavroudis, Dimitris;Perez, Edith A;Piccart-Gebhart, Martine ;Schneider, Bryan B.P.;Slamon, Dennis;Wolmark, Norman;Buyse, Marc
Référence Lancet oncology, 20, 3, page (361-370)
Publication Publié, 2019-03

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis
Auteur:	Saad, Everardo Delforge; Squifflet, Pierre; Burzykowski, Tomasz; Quinaux, Emmanuel; Delaloge, Suzette; Mavroudis, Dimitris; Perez, Edith A; Piccart-Gebhart, Martine; Schneider, Bryan B.P.; Slamon, Dennis; Wolmark, Norman; Buyse, Marc
Informations sur la publication:	Lancet oncology, 20, 3, page (361-370)
Statut de publication:	Publié, 2019-03
Sujet CREF:	Cancérologie
Note générale:	SCOPUS: ar.j
	DecretOANoAutActif
Langue:	Anglais
Identificateurs:	urn:issn:1470-2045
	info:doi/10.1016/S1470-2045(18)30750-2
	info:pii/S1470204518307502
	info:scp/85062172145
	info:pmid/30709633